AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6874967 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy couples
Number of subjects: 58
Study 6874967 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative behaviors of spouses
Number of subjects: 58
Study 6874967 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of negative behaviors
Number of subjects: 58
Study 6874967 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratings by spouses and observers
Number of subjects: 58
Study 30542740 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen gas inhalation for 3 hours/day at home
Number of subjects: 55
Study 30542740 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (not specified)
Number of subjects: 55
Study 29933407 — intervention group
Group type: EXPERIMENTAL
Intervention: IDEA protocol for structured expert elicitation
Number of subjects: 76
Study 26825258 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone-containing combined oral contraceptives (DRSP)
Number of subjects: 59510
Study 26825258 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-containing OCs (LNG)
Number of subjects: 59510
Study 26825258 — intervention group
Group type: COMPARATOR
Intervention: Other OCs
Number of subjects: 59510
Study 24647863 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic tubing training
Number of subjects: 49
Study 24647863 — intervention group
Group type: COMPARATOR
Intervention: Conventional resistance training
Number of subjects: 49
Study 22047681 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 4 g/day + Celecoxib 300 mg/day
Number of subjects: 60
Study 22047681 — intervention group
Group type: COMPARATOR
Intervention: L-carnitine 4 g/day + celecoxib 300 mg/day + megestrol acetate 320 mg/day
Number of subjects: 60
Study 19679216 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 (Rotarix)
Number of subjects: 10708
Study 19679216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10708
Study 22075812 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture technique (group A)
Number of subjects: 60
Study 22075812 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-plus-graft technique (group B)
Number of subjects: 60
Study 16053010 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily renal multivitamin containing folate (FA), vitamin B6 and B12 (5 mg, 10 mg and 0.4 mg respectively)
Number of subjects: 60
Study 16053010 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiological daily doses (15 mg, 100 mg and 1 mg)
Number of subjects: 60
Study 16053010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 60
Study 16053010 — intervention group
Group type: COMPARATOR
Intervention: Control group from the general population (N = 276)
Number of subjects: 60
Study 11812753 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (600 mg/day)
Number of subjects: 0
Study 11812753 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2,550 mg/day)
Number of subjects: 0
Study 10363745 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I (8 microg kg(‐1) h(‐1))
Number of subjects: 7
Study 10363745 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 7
Study 7491880 — intervention group
Group type: COMPARATOR
Intervention: 5 g fat
Number of subjects: 0
Study 7491880 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g fat
Number of subjects: 0
Study 7491880 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 g fat
Number of subjects: 0
Study 7491880 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g fat plus 50 g fructose
Number of subjects: 0
Study 7491880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (36 mg, or 120,000 U retinol)
Number of subjects: 0
Study 7491880 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fat loads
Number of subjects: 0
Study 7491880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sf 20-400 lipoprotein fraction
Number of subjects: 0
Study 1828420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 1.25 mg
Number of subjects: 60
Study 1828420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg
Number of subjects: 60
Study 1828420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 60
Study 1828420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 60
Study 1828420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1828420 — intervention group
Group type: EXPERIMENTAL
Intervention: All amlodipine doses
Number of subjects: 60
Study 1828420 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (all doses)
Number of subjects: 60
Study 6791200 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg haloperidol IM
Number of subjects: 6
Study 6791200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29925934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 117
Study 29925934 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/gemcitabine (CisGem)
Number of subjects: 117
Study 27601428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfemoral (TF) TAVR
Number of subjects: 2621
Study 27601428 — intervention group
Group type: EXPERIMENTAL
Intervention: Transapical (TA) TAVR
Number of subjects: 2621
Study 24613084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine
Number of subjects: 2499
Study 24613084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2499
Study 24613084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis
Number of subjects: 2499
Study 22191384 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavone extract (daily oral intake)
Number of subjects: 80
Study 22191384 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise and Mediterranean diet (Control group)
Number of subjects: 80
Study 20696032 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet
Number of subjects: 100
Study 20696032 — intervention group
Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 100
Study 18214607 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (5,000 IU) administered subcutaneously 20 to 30 min before ERCP
Number of subjects: 105
Study 18214607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution 0.5 ml) administered subcutaneously 20 to 30 min before ERCP
Number of subjects: 105
Study 18214607 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (5,000 IU)
Number of subjects: 105
Study 18214607 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution 0.5 ml)
Number of subjects: 105
Study 15845568 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT) with concurrent carboplatin 30 mg/m² per fraction up to the first 20 fractions.
Number of subjects: 46
Study 15845568 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone with irradiation of 60 Gy.
Number of subjects: 46
Study 12826150 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulect (20 mg, 30 minutes before reperfusion and 4 days after transplantation) and steroids
Number of subjects: 45
Study 10582540 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (VER) administered acutely
Number of subjects: 34
Study 10582540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 10582540 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (VER) administered intravenously (IV)
Number of subjects: 34
Study 10582540 — intervention group
Group type: EXPERIMENTAL
Intervention: Different oral formulations of Verapamil (VER)
Number of subjects: 34
Study 8945114 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centered counseling intervention
Number of subjects: 73
Study 8945114 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 73
Study 1768630 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky Performance Status (KPS) scale
Number of subjects: 209
Study 1768630 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG Performance Status (EPS) scale
Number of subjects: 209
Study 7225473 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual exposure to allergens
Number of subjects: 30
Study 7225473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30909252 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV coaching during neonatal bag-mask ventilation
Number of subjects: 0
Study 29649997 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention Group (MIG; no feedback)
Number of subjects: 227
Study 29649997 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching Group (CoachG; feedback on daily steps, MVPA, total EE with need supportive coaching)
Number of subjects: 227
Study 29649997 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching Group (CoachG)
Number of subjects: 227
Study 27646843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ricolinostat 160 mg once daily on days 1–21 of a 28 day cycle, in combination with lenalidomide 25 mg and dexamethasone 40 mg.
Number of subjects: 38
Study 23464813 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pregabalin
Number of subjects: 120
Study 23464813 — intervention group
Group type: COMPARATOR
Intervention: Transdermal fentanyl
Number of subjects: 120
Study 22795275 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI
Number of subjects: 549
Study 22795275 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + CFE
Number of subjects: 549
Study 22795275 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + Lines
Number of subjects: 549
Study 19893505 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 70
Study 19893505 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein supplementation
Number of subjects: 70
Study 19893505 — intervention group
Group type: COMPARATOR
Intervention: Glucose supplementation
Number of subjects: 70
Study 18570844 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac anal suppository after surgery
Number of subjects: 157
Study 18570844 — intervention group
Group type: COMPARATOR
Intervention: Control group without diclofenac
Number of subjects: 157
Study 15849209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal diamorphine 400 microg
Number of subjects: 80
Study 15849209 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal hyperbaric bupivacaine 0.5%
Number of subjects: 80
Study 12422496 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor (omega-3 fatty acid product)
Number of subjects: 0
Study 12378740 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7642049 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (Group A)
Number of subjects: 104
Study 7642049 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 104
Study 7642049 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (Group A) in inferior MI
Number of subjects: 104
Study 7642049 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (Group A) in anterior MI
Number of subjects: 104
Study 7642049 — intervention group
Group type: COMPARATOR
Intervention: Comparison of occluded vs patent infarct-related coronary artery
Number of subjects: 104
Study 7642049 — intervention group
Group type: COMPARATOR
Intervention: Comparison of patients with larger vs smaller EDVi after 3 months
Number of subjects: 104
Study 2613203 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate and 5‐fluorouracil
Number of subjects: 559
Study 2613203 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 559
Study 797543 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% halcinonide
Number of subjects: 60
Study 797543 — intervention group
Group type: COMPARATOR
Intervention: Active corticosteroid comparison drug
Number of subjects: 60
Study 30781962 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary sanation of the abdominal cavity (toilet, peroperative lavage, postoperative drainage)
Number of subjects: 55
Study 30781962 — intervention group
Group type: COMPARATOR
Intervention: Postoperative continuous lavage (irrigation with saline or another solution over 24-48 hours)
Number of subjects: 55
Study 27796035 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced medication plan with graphical and textual information on drug handling
Number of subjects: 120
Study 27796035 — intervention group
Group type: COMPARATOR
Intervention: Simple medication plan with standard information
Number of subjects: 120
Study 26193215 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF‐A
Number of subjects: 36
Study 26193215 — intervention group
Group type: EXPERIMENTAL
Intervention: ORM‐1
Number of subjects: 36
Study 26193215 — intervention group
Group type: EXPERIMENTAL
Intervention: ORM‐1 and VEGF‐A correlation
Number of subjects: 36
Study 23273975 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide therapy (dose of 3.3±2.1 mg/day for R230C vs 6.3±5 mg/day for R230R)
Number of subjects: 4
Study 23273975 — intervention group
Group type: COMPARATOR
Intervention: Control group (R230R participants)
Number of subjects: 4
Study 21067858 — intervention group
Group type: EXPERIMENTAL
Intervention: P and 2mg E2
Number of subjects: 285
Study 21067858 — intervention group
Group type: EXPERIMENTAL
Intervention: P and 4mg E2
Number of subjects: 285
Study 21067858 — intervention group
Group type: EXPERIMENTAL
Intervention: P and 6mg E2
Number of subjects: 285
Study 19906561 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and docetaxel followed by cyclophosphamide, epirubicin, and capecitabine (capecitabine group, n=753)
Number of subjects: 1500
Study 19906561 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by cyclophosphamide, epirubicin, and fluorouracil (control group, n=747)
Number of subjects: 1500
Study 19906561 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine group
Number of subjects: 1500
Study 19906561 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1500
Study 17289173 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab-coated stent
Number of subjects: 138
Study 17289173 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 138
Study 17289173 — intervention group
Group type: COMPARATOR
Intervention: Both groups (abciximab-coated stent and BMS)
Number of subjects: 138
Study 14763958 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 350
Study 14763958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 11290867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide 1500 mg/m2 in 1000 ml saline infused over 60 min, mesna 20% of total dose of ifosfamide in three doses for 3 days, mitoxantrone 12 mg/m2 on day 1; treatment repeated every 4 weeks for up to six cycles.
Number of subjects: 22
Study 9602591 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1
Number of subjects: 0
Study 9602591 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 0
Study 8014304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 5
Study 2682243 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous desmopressin (0.3 microgram per kilogram of body weight)
Number of subjects: 150
Study 2682243 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 150
Study 4836732 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Medium Slow (F M S) pace
Number of subjects: 8
Study 4836732 — intervention group
Group type: COMPARATOR
Intervention: Slow Medium Slow pace
Number of subjects: 8
Study 31783161 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) mediated antimicrobial photodynamic therapy (aPDT) along with scaling and root planing (SRP)
Number of subjects: 29
Study 31783161 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 29
Study 31293563 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdose 10,447 IU
Number of subjects: 144
Study 31293563 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdose 3,013 IU
Number of subjects: 144
Study 31293563 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdose 587 IU
Number of subjects: 144
Study 31293563 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdose 158 IU
Number of subjects: 144
Study 31293563 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdose 31 IU
Number of subjects: 144
Study 31293563 — intervention group
Group type: COMPARATOR
Intervention: Full dose 27,476 IU
Number of subjects: 144
Study 31293563 — intervention group
Group type: EXPERIMENTAL
Intervention: All subdoses (10,447 IU, 3,013 IU, 587 IU, 158 IU, 31 IU)
Number of subjects: 144
Study 31293563 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdoses above 587 IU
Number of subjects: 144
Study 31293563 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdoses (except for 31 IU)
Number of subjects: 144
Study 28379980 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tsDCS
Number of subjects: 12
Study 28379980 — intervention group
Group type: COMPARATOR
Intervention: Sham tsDCS
Number of subjects: 12
Study 26887214 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus moxibustion
Number of subjects: 200
Study 26887214 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (control)
Number of subjects: 200
Study 24348029 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration (WBV) at 30 Hz and 3.2 g for 5 minutes, three times per week for 6 months
Number of subjects: 28
Study 24348029 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 24348029 — intervention group
Group type: COMPARATOR
Intervention: Comparison between WBV and control groups
Number of subjects: 28
Study 22186118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate 100 mg
Number of subjects: 512
Study 22186118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate 300 mg
Number of subjects: 512
Study 22186118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate 1000 mg
Number of subjects: 512
Study 22186118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate 3000 mg
Number of subjects: 512
Study 22186118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 19226229 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil anesthesia with supplemental muscle relaxants (Group A)
Number of subjects: 56
Study 19226229 — intervention group
Group type: COMPARATOR
Intervention: Propofol and remifentanil anesthesia without supplemental muscle relaxants (Group B)
Number of subjects: 56
Study 16504757 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (Arm A): 500 mg/m2 5-fluorouracil, 12 mg/m2 mitoxantrone, and 500 mg/m2 cyclophosphamide with concomitant radiotherapy (50 Gy +/- 10-20-Gy boost)
Number of subjects: 638
Study 16504757 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy followed by radiotherapy (Arm B): 500 mg/m2 5-fluorouracil, 60 mg/m2 epirubicin, and 500 mg/m2 cyclophosphamide with subsequent radiotherapy
Number of subjects: 638
Study 16504757 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy (Arm A)
Number of subjects: 638
Study 16504757 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radiotherapy (Arm A)
Number of subjects: 638
Study 11967036 — intervention group
Group type: EXPERIMENTAL
Intervention: AM3 (3 g/day) for 30 consecutive days starting 15 days prior to the first vaccine dose
Number of subjects: 269
Study 11967036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g/day) for 30 consecutive days starting 15 days prior to the first vaccine dose
Number of subjects: 269
Study 10754365 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg i.v. erythromycin
Number of subjects: 12
Study 10754365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7550181 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36
Number of subjects: 332
Study 7550181 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol
Number of subjects: 332
Study 7550181 — intervention group
Group type: COMPARATOR
Intervention: Rosser classification and index
Number of subjects: 332
Study 1709338 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion
Number of subjects: 14
Study 1709338 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study 6788400 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. encainide 75 mg
Number of subjects: 9
Study 6788400 — intervention group
Group type: EXPERIMENTAL
Intervention: oral encainide 75 mg
Number of subjects: 9
Study 6788400 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 6380827 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy and insertion of 1 grommet on a side chosen at random
Number of subjects: 54
Study 6380827 — intervention group
Group type: COMPARATOR
Intervention: Control side (no grommet)
Number of subjects: 54
Study 29193211 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA 1g intravenous bolus followed by continuous infusion of TXA 1g over 8 hours
Number of subjects: 166
Study 29193211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 27765184 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day for 6 months
Number of subjects: 150
Study 27765184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24993769 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (0-0.06 U/min)
Number of subjects: 412
Study 24993769 — intervention group
Group type: COMPARATOR
Intervention: Noradrenaline (0-12 µg/min)
Number of subjects: 412
Study 24993769 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenous bolus six-hourly)
Number of subjects: 412
Study 24993769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 24993769 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin or Noradrenaline
Number of subjects: 412
Study 22576032 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting Heart System (RHS; Medtronic)
Number of subjects: 60